Daclatasvir-d6

Daclatasvir-[d6] is the stable isotope variant of Daclatasvir, a potent NS5A inhibitor used in combination therapies for hepatitis C virus (HCV) [1]. Daclatasvir inhibits the NS5A protein crucial for HCV replication, offering promise as part of interferon-free regimens that are increasingly favored in clinical practice [1]. It demonstrates pangenotypic activity against various HCV genotypes and has shown efficacy in both preclinical and clinical trials, highlighting its role in advancing HCV treatment strategies [2]. Despite its effectiveness, daclatasvir has a moderate barrier to resistance, necessitating ongoing research into combination therapies to enhance its durability [2]. The drug's safety profile supports its use in diverse patient populations, including those with challenging conditions like posttransplant and HIV co-infection [3]. Daclatasvir's development marks a significant advancement towards achieving ribavirin-free, all-oral therapies for hepatitis C, addressing a longstanding need in global healthcare [3].